Table 2.
Multivariate survival analysis.
| Variable | Overall Survival | Progression Free Survival | ||||||
|---|---|---|---|---|---|---|---|---|
| n | HR | 95% CI | p | n | HR | 95% CI | p | |
| 82 | 82 | |||||||
| Age (continuous) | 1.024 | 1–1.04 | 0.017 | 1.02 | 1–1.04 | 0.029 | ||
| ELN risk | ||||||||
| Low | 1 (ref) | |||||||
| Intermediate | 1.139 | 0.54–2.41 | 0.733 | 0.773 | 0.39–1.52 | 0.454 | ||
| High | 1.897 | 0.92–3.9 | 0.081 | 1.246 | 0.66–2.36 | 0.501 | ||
| BCL2-PI (continuous) | 1.578 | 1.1–2.27 | 0.014 | 1.547 | 1.09–2.19 | 0.014 | ||
| 82 | 82 | |||||||
| Age (continuous) | 1.023 | 1–1.04 | 0.024 | 1.022 | 1–1.04 | 0.017 | ||
| ELN risk | ||||||||
| Low | 1 (ref) | 1 (ref) | ||||||
| Intermediate | 1.208 | 0.57–2.55 | 0.62 | 0.72 | 0.37–1.42 | 0.341 | ||
| High | 1.896 | 0.92–3.9 | 0.082 | 1.262 | 0.66–2.39 | 0.477 | ||
| BCL2-PI (dichotomous) * | 1.764 | 0.95–3.28 | 0.073 | 1.749 | 1.04–2.95 | 0.036 | ||
| 60 | 60 | |||||||
| Age (continuous) | 1.032 | 1–1.06 | 0.021 | 1.022 | 1–1.04 | 0.017 | ||
| ELN risk | ||||||||
| Low | 1 (ref) | 1 (ref) | ||||||
| Intermediate | 0.979 | 0.38–2.5 | 0.965 | 0.568 | 0.25–1.3 | 0.18 | ||
| High | 1.739 | 0.71–4.28 | 0.229 | 0.98 | 0.45–2.12 | 0.959 | ||
| BCL2-CR (continuous) | 1.961 | 1.19–3.24 | 0.008 | 1.732 | 1.13–2.66 | 0.012 | ||
| 60 | 60 | |||||||
| Age (continuous) | 1.035 | 1.01–1.06 | 0.014 | 1.029 | 1–1.06 | 0.021 | ||
| ELN risk | ||||||||
| Low | 1 (ref) | 1 (ref) | ||||||
| Intermediate | 0.977 | 0.37–2.55 | 0.962 | 0.526 | 0.23–1.2 | 0.125 | ||
| High | 1.437 | 0.56–3.68 | 0.451 | 0.992 | 0.46–2.14 | 0.984 | ||
| BCL2-CR (dichotomous) * | 3.028 | 1.34–6.86 | 0.008 | 2.078 | 1.09–3.97 | 0.027 | ||
ELN, European LeukemiaNet 2010; BCL2-PI, BCL2 levels at post-induction; CR, complete remission; RL, relapse; * expression above AUC value (dichotomized); HR, Hazard Ratio; CI, Confidence Interval.